Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 93 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfJV4xKSzVyPUCuNFA3PjlizszN NIrJZWtUSU6JRWK=
MV-4-11 M{n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PT[2lEPTB;MD6wNVU5PiEQvF2= MYfTRW5ITVJ?
NKM-1 NWr2VGl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXPXVFKSzVyPUCuNFE3QTlizszN M2Lh[3NCVkeHUh?=
ML-2 M1LN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLUTWM2OD1yLkCxPVg{KM7:TR?= Mn7zV2FPT0WU
BV-173 NWnYRllHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXHemIyUUN3ME2wMlAzOzF2IN88US=> M3\aOXNCVkeHUh?=
RS4-11 NXHVVlR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHiR2M4UUN3ME2wMlAzPTh5IN88US=> NFXFdlJUSU6JRWK=
HL-60 NHPObllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXKTWM2OD1yLkCyPVA5KM7:TR?= NH64SZdUSU6JRWK=
KY821 NUHYZYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEK5O|Uh|ryP NH3YNI1USU6JRWK=
ECC10 NH:2c2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrxTWM2OD1yLkCzO|kzKM7:TR?= Moj0V2FPT0WU
NCI-H720 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzncmtIUUN3ME2wMlA1ODFzIN88US=> MWfTRW5ITVJ?
QIMR-WIL NXrVWIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS5NXpKSzVyPUCuNFQzQDdizszN MUjTRW5ITVJ?
KG-1 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESycYlKSzVyPUCuNFQ1QDZizszN MULTRW5ITVJ?
TGW M3rCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLJOXBKUUN3ME2wMlA1PjN|IN88US=> MV7TRW5ITVJ?
ATN-1 NYHFe3dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{izbWlEPTB;MD6wOFc{OyEQvF2= MWjTRW5ITVJ?
RH-18 NHu0cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LJRWlEPTB;MD6wOlA1QCEQvF2= NV3ETmd2W0GQR1XS
EW-18 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwME[4OFEh|ryP MXHTRW5ITVJ?
NB17 M1;0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEexNlQh|ryP NHPPTVFUSU6JRWK=
SK-NEP-1 NIPDVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTIeo5jUUN3ME2wMlA4OjF|IN88US=> NXLaVZk6W0GQR1XS
P12-ICHIKAWA MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y2bWlEPTB;MD6wO|c4QCEQvF2= MlLlV2FPT0WU
KARPAS-45 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW0TWM2OD1yLkC3PFE2KM7:TR?= NG\BPVVUSU6JRWK=
EW-3 M4[1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXqS3F1UUN3ME2wMlA5ODV|IN88US=> MY\TRW5ITVJ?
NB13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG2TWM2OD1yLkC4NlA{KM7:TR?= NH76TWhUSU6JRWK=
NCI-H209 NG\aZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL6Z5RKSzVyPUCuNFg4ODRizszN MkHlV2FPT0WU
NCI-H1092 NHjTU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUCyO|Uh|ryP MWDTRW5ITVJ?
NH-12 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTWTWM2OD1yLkGwO|Q1KM7:TR?= M4H6fHNCVkeHUh?=
697 NE\DcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWxTWM2OD1yLkGwPFM6KM7:TR?= MXzTRW5ITVJ?
KE-37 M2r1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\STWM2OD1yLkGxN|ch|ryP NX[1Sm06W0GQR1XS
MOLT-4 M{G1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOxfmxzUUN3ME2wMlE2OTZ7IN88US=> NWHqdIVCW0GQR1XS
CHP-134 MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPER49KSzVyPUCuNVY{ODZizszN M3\5NXNCVkeHUh?=
D-283MED MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\SR2lEPTB;MD6xO|Y5PiEQvF2= MWLTRW5ITVJ?
LU-135 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMUi1OVIh|ryP NVX6T|RTW0GQR1XS
LU-134-A M2HtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HWe2lEPTB;MD6xPFY4OSEQvF2= NXvuWZg1W0GQR1XS
EM-2 M4XFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrZOFdKSzVyPUCuNVk6OThizszN MULTRW5ITVJ?
LU-139 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnQSXpKSzVyPUCuNlA1QThizszN MXPTRW5ITVJ?
ALL-PO NGjiepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMkG5PFgh|ryP Mk\IV2FPT0WU
NB12 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGxTWM2OD1yLkKzNVE2KM7:TR?= MXLTRW5ITVJ?
KP-N-YN M1LlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrETWM2OD1yLkKzOVc{KM7:TR?= NVjBSFNiW0GQR1XS
BEN NH3YXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nmdGlEPTB;MD6yN|k3QCEQvF2= NFTIRXNUSU6JRWK=
HCC1569 M2nX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln5TWM2OD1yLkK1NVA3KM7:TR?= Mlm2V2FPT0WU
HuO9 NYDhO3NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMk[3NVUh|ryP NInNSJNUSU6JRWK=
WM-115 NEjoTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLSUnVKSzVyPUCuNlc4OzhizszN NFLmUVhUSU6JRWK=
CCRF-CEM NFjNfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X3N2lEPTB;MD6zN|UzQSEQvF2= NISxOIJUSU6JRWK=
IST-SL1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\VTWM2OD1yLkO1N|Q{KM7:TR?= M4G0enNCVkeHUh?=
BE-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f3cmlEPTB;MD6zOlQ2QSEQvF2= MY\TRW5ITVJ?
COR-L88 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnQeXpKSzVyPUCuN|Y2PCEQvF2= M{fITnNCVkeHUh?=
DOHH-2 NX7pWnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfTTWM2OD1yLkSxNFI{KM7:TR?= MlXUV2FPT0WU
A704 M1;adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH4UoxKSzVyPUCuOFI3PyEQvF2= NGfST3lUSU6JRWK=
KNS-81-FD M3n3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwNESwNVch|ryP MmjZV2FPT0WU
RPMI-8226 NW\WdYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfjfGQxUUN3ME2wMlQ2PjV{IN88US=> M33Bd3NCVkeHUh?=
TGBC24TKB NF\wU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV33dFFKUUN3ME2wMlQ2Pzd6IN88US=> NXLFSpRZW0GQR1XS
NCI-H1304 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNE[xOVch|ryP Mo\GV2FPT0WU
MOLT-13 M2j2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwNE[2NVMh|ryP M1;jSXNCVkeHUh?=
EW-22 NI\0RYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjaeXBKSzVyPUCuOFY3PzFizszN MUXTRW5ITVJ?
MS-1 NV25Roo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNE[5N|Mh|ryP NXvkbng2W0GQR1XS
RMG-I M2nvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwNEm0OlQh|ryP MkniV2FPT0WU
NTERA-S-cl-D1 NIrZPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4TWM2OD1yLkWwNFE6KM7:TR?= MYDTRW5ITVJ?
NCI-H1048 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNUC5OVMh|ryP M33Fe3NCVkeHUh?=
SW1417 NGTiTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHzRph6UUN3ME2wMlU2PDN6IN88US=> Ml\LV2FPT0WU
DB NInQ[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPt[WRKSzVyPUCuOVcxQCEQvF2= Mnf5V2FPT0WU
MEG-01 M2\oNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjxNlBKSzVyPUCuOVg{OiEQvF2= MnrUV2FPT0WU
EW-13 NVLqN3hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqzOXg{UUN3ME2wMlU5OzRzIN88US=> NHjrSGFUSU6JRWK=
LAMA-84 NH[3T2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fLZWlEPTB;MD61PVIxPyEQvF2= MX\TRW5ITVJ?
J-RT3-T3-5 M4T4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\lO2lEPTB;MD62NFgxQCEQvF2= M3juNHNCVkeHUh?=
MOLT-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwNkWyOlQh|ryP NXTQR5BmW0GQR1XS
DU-4475 NICyV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmwR3VOUUN3ME2wMlY2PDJ5IN88US=> NWPtN5U4W0GQR1XS
HAL-01 NHfEcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwN{K1OFkh|ryP MlLUV2FPT0WU
RD MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfCc2FyUUN3ME2wMlc2QDl7IN88US=> MUjTRW5ITVJ?
OAW-28 NWi3SIhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr2TWM2OD1yLke4N|ch|ryP MV\TRW5ITVJ?
HCC38 NV61R3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwOECxPUDPxE1? MWDTRW5ITVJ?
NMC-G1 NYLyfpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTwSVAxUUN3ME2wMlgyOTJzIN88US=> NEfIeHZUSU6JRWK=
EW-16 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwOEGzNlgh|ryP MljXV2FPT0WU
DU-145 M3;XNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf2[ZJKSzVyPUCuPFk6OjNizszN M4W5N3NCVkeHUh?=
HPAF-II NEfrW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\LTWM2OD1yLkmyOlI5KM7:TR?= NFnXU2VUSU6JRWK=
A427 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwOUOwNlIh|ryP M1m4e3NCVkeHUh?=
PA-1 NX;zemh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLCTWM2OD1yLkm1OlQzKM7:TR?= MoDwV2FPT0WU
OAW-42 NGjI[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHWeGxGUUN3ME2wMlk3OTR4IN88US=> MorrV2FPT0WU
L-428 NX;N[Y9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G5R2lEPTB;MT6wNVI2KM7:TR?= MWTTRW5ITVJ?
COLO-824 NILmOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3CR2RKSzVyPUGuNFE4ODhizszN NW\4bWI4W0GQR1XS
P30-OHK NYfSb|hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrRXm5uUUN3ME2xMlA1Pjh6IN88US=> MkfWV2FPT0WU
NCI-H2170 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwME[yN{DPxE1? M175RXNCVkeHUh?=
HCC2998 NYq4OoVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwMEexN|Uh|ryP MlrnV2FPT0WU
NB14 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMUO3OFgh|ryP NUDZWmJ1W0GQR1XS
TGBC1TKB MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHFdmRKSzVyPUGuNVQyPTJizszN NYfaeIVxW0GQR1XS
KP-N-YS NXjZcJpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe0TI5vUUN3ME2xMlE3OjN4IN88US=> Ml7aV2FPT0WU
CAL-120 NVTyb3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMU[0Nlkh|ryP NX7Re5FXW0GQR1XS
SBC-1 NEC3bGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi3N2lKSzVyPUGuNVkxPTNizszN M3faOnNCVkeHUh?=
C32 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DZUmlEPTB;MT6xPVA5QCEQvF2= M3rTbnNCVkeHUh?=
HCC2157 NUfG[JNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[3TGQ5UUN3ME2xMlE6PDl2IN88US=> MlPJV2FPT0WU
COLO-792 NEi3[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfK[FhKSzVyPUGuNlAxPzFizszN MlPVV2FPT0WU
ES7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwMke5OVEh|ryP NFfscllUSU6JRWK=
HEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWzOllWUUN3ME2xMlMyODJ7IN88US=> MVzTRW5ITVJ?
ES4 MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP1S5RKSzVyPUGuN|Q6QThizszN MoXxV2FPT0WU
NCI-SNU-1 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD1zLkO2OVU2KM7:TR?= NEHBOHdUSU6JRWK=
MDA-MB-415 NIm2XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i0U2lEPTB;MT6zPFg2KM7:TR?= MmntV2FPT0WU
NCI-H2342 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXrfYxyUUN3ME2xMlQxOjZ7IN88US=> MYjTRW5ITVJ?
NB69 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwNE[yO|Eh|ryP MUfTRW5ITVJ?
D-247MG NW\1UIVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jJdWlEPTB;MT61NVEzOiEQvF2= M4jmOXNCVkeHUh?=
SCC-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES1[VhKSzVyPUGuOVk5QDdizszN NXHDb2duW0GQR1XS
HuH-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXlTWM2OD1zLk[3Nlk{KM7:TR?= NGrH[ndUSU6JRWK=
A388 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwNki3NlQh|ryP M3ToZnNCVkeHUh?=
Calu-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\KTWM2OD1zLkewOlk4KM7:TR?= MmPIV2FPT0WU
NCI-H1648 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT2[oFKSzVyPUGuO|E1OThizszN MlnBV2FPT0WU
NCI-H2052 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn0TWM2OD1zLkeyNlAyKM7:TR?= NHrQZ2FUSU6JRWK=
Ramos-2G6-4C10 NYj2bpZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fMZWlEPTB;MT63N|Y2PiEQvF2= M4jofXNCVkeHUh?=
DEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\RUWlEPTB;MT63OFY6OiEQvF2= MmXRV2FPT0WU
SNU-423 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLwd|YyUUN3ME2xMlc5OTV5IN88US=> Ml7KV2FPT0WU
COR-L23 M1PkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLXTWM2OD1zLke5PFc1KM7:TR?= Mn\UV2FPT0WU
OMC-1 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln3TWM2OD1zLki2NFE3KM7:TR?= MX\TRW5ITVJ?
EW-11 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknRTWM2OD1zLkm1OlU4KM7:TR?= MXjTRW5ITVJ?
HSC-3 NX\sXJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn4NItKSzVyPUGuPVY{PjVizszN MX\TRW5ITVJ?
MLMA MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TqWGlEPTB;MT65OlY4PyEQvF2= NEPxNo9USU6JRWK=
RCM-1 NHXz[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqzRnVGUUN3ME2yMlAxOzl7IN88US=> M{DNOXNCVkeHUh?=
MFE-280 NIq1OVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwMEK4OFgh|ryP NIGxfFhUSU6JRWK=
ES8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe4NoNKSzVyPUKuNlU1PzFizszN NIjMUJlUSU6JRWK=
TE-11 M3v0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f5Z2lEPTB;Mj6yPVQ4OyEQvF2= M4H6b3NCVkeHUh?=
HuO-3N1 NHj1bWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne3TWM2OD1{LkS4O|gh|ryP M{LGNnNCVkeHUh?=
MHH-NB-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImzcnZKSzVyPUKuOVEyPThizszN NH7McIpUSU6JRWK=
TGBC11TKB MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PndmlEPTB;Mj61O|Y5OSEQvF2= MWPTRW5ITVJ?
HOP-92 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnXTWM2OD1{LkW4O|Q{KM7:TR?= NIDnOJNUSU6JRWK=
IGR-1 M{[wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MneyTWM2OD1{Lk[yNFM2KM7:TR?= MnPmV2FPT0WU
GOTO M1THO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzxUoVQUUN3ME2yMlY2Ozd5IN88US=> MljGV2FPT0WU
NCI-H1650 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnGTWM2OD1{LkeyNlE2KM7:TR?= MlfHV2FPT0WU
NCI-H1581 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrqO4xKSzVyPUKuO|k3QDFizszN NFHaTJJUSU6JRWK=
NCI-H2405 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULvcnRHUUN3ME2yMlgzPzh{IN88US=> NGrQUWhUSU6JRWK=
U-118-MG M{W5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrRTWM2OD1{Lkm2OFkyKM7:TR?= NVTENIJvW0GQR1XS
DoTc2-4510 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i5ZmlEPTB;Mz6wNVQyPyEQvF2= MkLpV2FPT0WU
NCI-H596 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO4WIZsUUN3ME2zMlA1QTl5IN88US=> NHnyPZlUSU6JRWK=
MPP-89 NVH4[mtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ETWM2OD1|LkC1OlY3KM7:TR?= M4OyPXNCVkeHUh?=
GCIY NVzkSGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fnfmlEPTB;Mz6yNFQ6OSEQvF2= MU\TRW5ITVJ?
SW626 NUTYZXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInUTJVKSzVyPUOuNlQ2PDNizszN M{nVWHNCVkeHUh?=
OCI-AML2 NUTK[3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvC[WdKSzVyPUOuN|EzPzJizszN M1y4RXNCVkeHUh?=
NBsusSR NHrmPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P0[mlEPTB;Mz6zOFk{QCEQvF2= NHPCR5NUSU6JRWK=
AN3-CA MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33q[2lEPTB;Mz60OFI{QCEQvF2= M2DVZ3NCVkeHUh?=
EFM-19 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjXTWM2OD1|LkS4N|M6KM7:TR?= NUP3N2tEW0GQR1XS
RVH-421 M{\zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnyTIl6UUN3ME2zMlU3QDd5IN88US=> NVu0V5lkW0GQR1XS
5637 M3jK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS1N3lrUUN3ME2zMlYyOTB|IN88US=> NHPYV4xUSU6JRWK=
PANC-08-13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIWxbohKSzVyPUOuOlM1PzJizszN NYDuWG5MW0GQR1XS
H9 M3e0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULaR5NUUUN3ME2zMlY4OTR2IN88US=> MWXTRW5ITVJ?
KARPAS-299 M4LheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwNkezOlEh|ryP Mmi5V2FPT0WU
TE-5 NUDkVoV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHXTWM2OD1|LkewO|A6KM7:TR?= NVn3c4pDW0GQR1XS
NOS-1 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDrPI5KSzVyPUOuO|k5OzRizszN MmrVV2FPT0WU
HH Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzHXoRKSzVyPUOuPFM5PjhizszN M365d3NCVkeHUh?=
769-P M3rRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr4colpUUN3ME2zMlg6PTFizszN NHfHUG1USU6JRWK=
CHP-212 MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm4TWM2OD1|LkmyOVQ6KM7:TR?= NXHK[nRVW0GQR1XS
NCI-H82 M3rlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3GSXpKSzVyPUOuPVU6OzZizszN M2G0VHNCVkeHUh?=
Mo-T NGXrN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\GTWM2OD12LkC0N|EzKM7:TR?= MofCV2FPT0WU
BB65-RCC NHvaXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIXWlEPTB;ND6wOFM6QSEQvF2= NFPrWYNUSU6JRWK=
SW1990 M{LJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS5Sm1KSzVyPUSuNFU6ODhizszN NUnafFFvW0GQR1XS
LK-2 NFTUZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fENWlEPTB;ND6xNVI6OyEQvF2= M2n2R3NCVkeHUh?=
ES5 NFzUbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwMUO5PFUh|ryP NWTiW5M2W0GQR1XS
JVM-3 NGDZSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwMUiyNlIh|ryP NWHOW2tTW0GQR1XS
RPMI-7951 NWfKeoh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqRYhKSzVyPUSuNlI1OTNizszN MYXTRW5ITVJ?
Calu-6 M2\UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwMke4PFEh|ryP NVHMbI52W0GQR1XS
LC-2-ad M2HPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLBOJlKSzVyPUSuNlk2PjhizszN MnX6V2FPT0WU
SW954 M17yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXYRlA2UUN3ME20MlI6PjZizszN NWnpWFVzW0GQR1XS
H-EMC-SS NYDVZok2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXTS|B6UUN3ME20MlMyQDNzIN88US=> NHPsPHhUSU6JRWK=
ES3 NX\aZnR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{eyfmlEPTB;ND6zOVQ1OSEQvF2= MoDGV2FPT0WU
no-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX4TWM2OD12LkO1OVU1KM7:TR?= MYfTRW5ITVJ?
LAN-6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PFcGlEPTB;ND60OVE5QSEQvF2= MVTTRW5ITVJ?
FTC-133 NF3PSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwNUO5OUDPxE1? M2DnU3NCVkeHUh?=
8505C NGizO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLJTWM2OD12LkW0NlMh|ryP NWXp[pRSW0GQR1XS
SW620 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfZcG5KSzVyPUSuOVcxPTdizszN M372XXNCVkeHUh?=
BCPAP M1rFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjHTWM2OD12Lk[zOFgyKM7:TR?= NH;Vc5RUSU6JRWK=
SK-LU-1 M17HVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13TUmlEPTB;ND62OlA5QSEQvF2= NUTJc|U4W0GQR1XS
NCI-H1623 NGi2fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRwN{CyNlgh|ryP NGrkVnNUSU6JRWK=
C2BBe1 NFTOc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwN{SwNFgh|ryP MX;TRW5ITVJ?
GP5d MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[1TWM2OD12Lke4N|g5KM7:TR?= M{fuT3NCVkeHUh?=
NB6 NEXr[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwOE[yNFQh|ryP MWjTRW5ITVJ?
MDA-MB-157 NUHTSIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHjTWM2OD12Lki4O|Yh|ryP NUfuVVdMW0GQR1XS
UMC-11 NWHhPFN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTRwOEi5OlQh|ryP M2OyeXNCVkeHUh?=
HCC1419 NX3meHg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPKOG5KSzVyPUSuPVAxPjNizszN M1fpXXNCVkeHUh?=
NCI-H2029 M4nPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;WcmpKSzVyPUSuPVQyQDVizszN NFrpZplUSU6JRWK=
LXF-289 NHG5ZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXWNWxKSzVyPUWuNFM4OTlizszN M2\IXnNCVkeHUh?=
KINGS-1 M1vON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS4NoJKSzVyPUWuNFc4PDRizszN Mk\qV2FPT0WU
HD-MY-Z NXrUOItGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTVwMkO5Olkh|ryP MV\TRW5ITVJ?
ESS-1 M4XUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrtd2dFUUN3ME21MlI2PTl5IN88US=> M4LLTnNCVkeHUh?=
GI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D1VWlEPTB;NT6yO|kzPiEQvF2= MkH1V2FPT0WU
RPMI-2650 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\VTWM2OD13LkO2NVYh|ryP NH7WV5NUSU6JRWK=
IA-LM NX;HZpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T1NmlEPTB;NT6zPVg4OSEQvF2= MWfTRW5ITVJ?
KP-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTVwNE[zN|Qh|ryP NEH0d|JUSU6JRWK=
G-402 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTVwNUG4OlUh|ryP MlPGV2FPT0WU
OS-RC-2 NGLvSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPOTWM2OD13LkWyOlA1KM7:TR?= MVPTRW5ITVJ?
NCI-H1155 NX3oenQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX4UFNCUUN3ME21MlU1QTV3IN88US=> NGLaNXVUSU6JRWK=
OE19 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS3TWM2OD13Lk[4OlI1KM7:TR?= M4Ht[HNCVkeHUh?=
U-2-OS NVLvcGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37RPGlEPTB;NT64PVAyOyEQvF2= MULTRW5ITVJ?
SCC-15 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL4NFZoUUN3ME21Mlk{PjZ{IN88US=> MkDXV2FPT0WU
NCI-H630 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fDfmlEPTB;NT65PVQxPCEQvF2= MXfTRW5ITVJ?
PFSK-1 NITTdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwMEWyOVkh|ryP NH3ZUVVUSU6JRWK=
NCI-H1770 NWrlRYVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3lTWM2OD14LkKwPFc1KM7:TR?= M13iUnNCVkeHUh?=
SK-MEL-3 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XMcWlEPTB;Nj60NlkyPSEQvF2= M2fPZXNCVkeHUh?=
LB1047-RCC MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTZwNEe2NlUh|ryP NEPmUlFUSU6JRWK=
NCI-H446 NEfjWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTLOnJ5UUN3ME22MlYzQTJ3IN88US=> MkjSV2FPT0WU
SW780 NEm1cWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDzW3pHUUN3ME22MlcxOTh3IN88US=> MlH0V2FPT0WU
NEC8 NI\0SGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTn[ItKSzVyPU[uO|Y3OyEQvF2= MoLOV2FPT0WU
NOMO-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjxV4JKSzVyPU[uO|gyOTFizszN NXmySXpqW0GQR1XS
COLO-668 NH7WS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r0XWlEPTB;Nj64OFM5PyEQvF2= MkP1V2FPT0WU
MC116 M4j5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfWTJJKSzVyPU[uPVM5QTdizszN NG\GRVRUSU6JRWK=
HCC1937 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ruOWlEPTB;Nj65PVI2OSEQvF2= NV;MXpVwW0GQR1XS
NCI-N87 NYnGRZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3NZpZKSzVyPUeuNVkzQTNizszN NVOxPINRW0GQR1XS
COLO-320-HSR NVPXdFNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXriNnVsUUN3ME23MlIzPzN6IN88US=> NH7YR5VUSU6JRWK=
HCC1806 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF61[4FKSzVyPUeuNlYxPDRizszN MnzEV2FPT0WU
OVCAR-3 NXrYWZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfYWXNlUUN3ME23MlM{ODN6IN88US=> MWLTRW5ITVJ?
NUGC-3 M1j1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzofFBVUUN3ME23MlM6Pjl2IN88US=> M3PTRXNCVkeHUh?=
SW1783 NIWxNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjOTWM2OD15LkSzNVc2KM7:TR?= MYjTRW5ITVJ?
GCT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfOTWM2OD15LkW2PVA3KM7:TR?= NUPafWE{W0GQR1XS
NCI-H2126 NYPadGw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTdwN{O2NlUh|ryP M2T5cnNCVkeHUh?=
MEL-HO M1frTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTDd2pVUUN3ME23Mlc4ODV2IN88US=> NGTMXmNUSU6JRWK=
CAPAN-1 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTqWZRrUUN3ME23Mlc4OzV5IN88US=> MV7TRW5ITVJ?
SW756 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DjS2lEPTB;Nz63PFM{OyEQvF2= MkntV2FPT0WU
SKG-IIIa NVHZcJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXroSJlKUUN3ME23MlgyQDl{IN88US=> NEHQc5lUSU6JRWK=
HCE-T NXXNd4g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXKe|hWUUN3ME23Mlg4Pzh|IN88US=> NHfCZYlUSU6JRWK=
Ca-Ski MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO0TWM2OD15Lkm5N|g{KM7:TR?= NWTYZ4lMW0GQR1XS
COLO-684 M2LWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRThwMEG4NVgh|ryP M1vFbXNCVkeHUh?=
KYSE-70 M2jPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRThwMEe3Nlkh|ryP M33rW3NCVkeHUh?=
TI-73 NWS4V2puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjoUHdTUUN3ME24MlI2QDVzIN88US=> MnzkV2FPT0WU
BT-20 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqwT49KSzVyPUiuNlYxPTJizszN NFPIdJpUSU6JRWK=
MHH-ES-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRThwNUG4N|Qh|ryP NUW4U4p1W0GQR1XS
TE-12 NXflfolXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDyU|VKSzVyPUiuOVk6OzFizszN NIfRSZFUSU6JRWK=
YH-13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT0RYdUUUN3ME24MlYyODB6IN88US=> NGHEeJVUSU6JRWK=
SF126 NUHiTIFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HifmlEPTB;OD64N|g3PSEQvF2= MWTTRW5ITVJ?
J82 NV\NRm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPjTWM2OD16LkmwNFM5KM7:TR?= NH7Bb4JUSU6JRWK=
RCC10RGB NHm0XVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDRUoVKSzVyPUiuPVk2PjFizszN NHHvN2hUSU6JRWK=
SK-UT-1 NGXDVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rTbWlEPTB;OT6wOFk1PSEQvF2= MojZV2FPT0WU
LB2241-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTBZ2RVUUN3ME25MlE6OTN5IN88US=> NF[2PGVUSU6JRWK=
LB996-RCC NHfre2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTlwMUm4PUDPxE1? NUn1NnV5W0GQR1XS
EPLC-272H MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rDTmlEPTB;OT6zO|Y2PyEQvF2= MWnTRW5ITVJ?
CTV-1 NHm2TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0V3ZQUUN3ME25MlU3PTN{IN88US=> MoLoV2FPT0WU
HSC-2 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTlwNUe1OUDPxE1? MXrTRW5ITVJ?
SK-MEL-28 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXCTWM2OD17Lk[xPFk{KM7:TR?= NIPtcJhUSU6JRWK=
MMAC-SF NFnITIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH2eYFKSzVyPUmuOlg4PSEQvF2= MljlV2FPT0WU
CP50-MEL-B M{LtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33GNGlEPTB;OT63OVc5OiEQvF2= NFz2NppUSU6JRWK=
HT-1080 NX72XFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L5fmlEPTB;OT63O|c{QSEQvF2= NUjtOmROW0GQR1XS
HEC-1 NFraV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnqTWM2OD1zMD6zN|UzKM7:TR?= MYLTRW5ITVJ?
AGS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX2TWM2OD1zMD6zO|Qh|ryP MXrTRW5ITVJ?
GAMG NYTRbmx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y2UWlEPTB;MUCuOVE3OiEQvF2= M4fn[3NCVkeHUh?=
SW48 NYPlUHlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFyLkWxPFkh|ryP NWixN5hlW0GQR1XS
U031 M3LsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrXVJRsUUN3ME2xNE42QTB6IN88US=> M2ixSnNCVkeHUh?=
OVCAR-5 M2rCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrIUoZQUUN3ME2xNE43PDJ7IN88US=> M4XSbXNCVkeHUh?=
SF295 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFyLk[3NFQh|ryP Mn7FV2FPT0WU
BHT-101 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjJ[llKSzVyPUGwMlcyPzdizszN NVPLdmJ3W0GQR1XS
VMRC-RCZ M4PneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv5fGlKSzVyPUGxMlMzODFizszN MWnTRW5ITVJ?
ACHN NF:1fZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFzLkSyNVEh|ryP NX;BfFZsW0GQR1XS
NCI-H526 NGjkeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnSPFlbUUN3ME2xNU42ODR|IN88US=> MlP4V2FPT0WU
MN-60 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi1TWM2OD1zMT61N|kh|ryP NUfxNoR5W0GQR1XS
NCI-H2291 NF3iZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO4cGFKSzVyPUGxMlU1PjZizszN M2XPN3NCVkeHUh?=
SCC-25 M2n2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7nc|RKSzVyPUGxMlc2PTZizszN MlnXV2FPT0WU
SK-MEL-2 NEXkOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jFOGlEPTB;MUGuO|Y{PyEQvF2= MW\TRW5ITVJ?
SN12C NVzqUIlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH64XY9KSzVyPUGxMlk{PTVizszN MkDGV2FPT0WU
NCI-H69 NHPtdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrsS5V5UUN3ME2xNk41OjN2IN88US=> M3O4ZnNCVkeHUh?=
ME-180 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\5[GlEPTB;MUKuO|A2PCEQvF2= NVnZVpZVW0GQR1XS
MC-IXC NH\WUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[1TWM2OD1zMj63OVE5KM7:TR?= NFjlXGRUSU6JRWK=
NCI-H2347 M37zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjsTWM2OD1zMj63OlE1KM7:TR?= NVPS[ZZ2W0GQR1XS
M059J MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsTWM2OD1zMj63O|I4KM7:TR?= NYTuZVhIW0GQR1XS
A2058 NGfYco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLXW5ZnUUN3ME2xNk45PjhzIN88US=> NGm2cItUSU6JRWK=
VA-ES-BJ M3j4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHoV4tKSzVyPUGyMlg4QDVizszN NFL6flJUSU6JRWK=
Ca9-22 NXf6[IViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTsTWM2OD1zMj65OFUyKM7:TR?= MU\TRW5ITVJ?
KNS-42 NILxUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXzUFB3UUN3ME2xNk46QTh2IN88US=> NXfL[FNkW0GQR1XS
LoVo NGW3elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:5TWM2OD1zMz6yN|E{KM7:TR?= NI\HcGpUSU6JRWK=
AM-38 NUjvZWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWexcXRLUUN3ME2xN{4zPTZ4IN88US=> NYXNfY9qW0GQR1XS
NB5 M3nWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF|LkO3OVIh|ryP NGX2NYtUSU6JRWK=
L-363 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XjT2lEPTB;MUOuOFA{OyEQvF2= NYD5bVI6W0GQR1XS
SK-MEL-30 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF2LkC2OFUh|ryP MonMV2FPT0WU
NCI-H1563 NVXBSHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjuTWM2OD1zND62NFM6KM7:TR?= NIrnPZBUSU6JRWK=
NCI-H2228 M1\Ee2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnGPYJKSzVyPUG0MlYxPzdizszN NXr2SW9YW0GQR1XS
MFM-223 NWPSfHNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HVNGlEPTB;MUWuNVgyOyEQvF2= M1vKUnNCVkeHUh?=
LB831-BLC M1P1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fHbGlEPTB;MUWuNlc3PyEQvF2= NYr1NW52W0GQR1XS
SW872 M4nTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXmTWM2OD1zNT6zNFg3KM7:TR?= MX3TRW5ITVJ?
NCI-H522 M2f0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrZe4FKSzVyPUG1MlM{ODZizszN NE\qdYZUSU6JRWK=
EW-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTPRoxxUUN3ME2xOU42PDZ{IN88US=> MWPTRW5ITVJ?
HN NHfpUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\DOGFvUUN3ME2xOU42QTR{IN88US=> NVjrRZRmW0GQR1XS
SW837 M1rNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjKXG5KSzVyPUG1Mlc5PDdizszN MkHCV2FPT0WU
SCC-9 M1nsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF3LkixNVQh|ryP NImz[nhUSU6JRWK=
MKN7 NHrVcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rpSGlEPTB;MUWuPVc{OiEQvF2= NYn0cWxbW0GQR1XS
KYSE-410 M2P0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvWTWM2OD1zNj61PVEh|ryP NH\1OYxUSU6JRWK=
SK-N-DZ MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHjSndKSzVyPUG2MlYyOTZizszN M1vVd3NCVkeHUh?=
COR-L105 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF4Lk[1Nlgh|ryP M33nTXNCVkeHUh?=
LB2518-MEL NG\SfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n0OmlEPTB;MU[uPFM5QSEQvF2= MmfFV2FPT0WU
OVCAR-4 M1W3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC4TodKSzVyPUG2Mlg5PjJizszN MVLTRW5ITVJ?
TK10 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLxVmZKSzVyPUG2Mlk1PzNizszN M{XYcnNCVkeHUh?=
KNS-62 NUS2W45JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y2N2lEPTB;MU[uPVc4PyEQvF2= MkO4V2FPT0WU
RPMI-8866 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvlfYJnUUN3ME2xO{4yPzN{IN88US=> MmLvV2FPT0WU
HuP-T4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DifmlEPTB;MUeuNlQ6PSEQvF2= NInWfnZUSU6JRWK=
CGTH-W-1 NHn6dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIezc3pKSzVyPUG3MlUzOTlizszN MlPrV2FPT0WU
T-24 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIiyeYFKSzVyPUG3MlU{PDdizszN MoXVV2FPT0WU
HT-3 M4PDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF5LkW5NVQh|ryP M4H3THNCVkeHUh?=
KS-1 NIPGVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\lXXJKSzVyPUG3MlY4OyEQvF2= NGXWXmRUSU6JRWK=
NCI-H1792 NV71NZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe3OnpQUUN3ME2xO{44QThizszN NHSzNWRUSU6JRWK=
ABC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnnenF3UUN3ME2xO{45OTRzIN88US=> NHXNT3BUSU6JRWK=
BPH-1 NH;2W5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ITWM2OD1zOD6xOlg2KM7:TR?= NVvhOllOW0GQR1XS
A431 NGTTXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nJcmlEPTB;MUiuOFEzPyEQvF2= NG\WT2hUSU6JRWK=
T98G NFHSO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILVc4ZKSzVyPUG4MlUyPTdizszN NFTDUFhUSU6JRWK=
BHY NYDuUXVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLzTWM2OD1zOD64Olkh|ryP MWfTRW5ITVJ?
Capan-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF6LkmwO|gh|ryP MWrTRW5ITVJ?
MDA-MB-175-VII Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzkTWM2OD1zOD65NlA6KM7:TR?= NFfFeINUSU6JRWK=
CAL-27 NHrCNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zxUGlEPTB;MUmuNFQ5PyEQvF2= M1jUdHNCVkeHUh?=
AsPC-1 NIna[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF7Lki2OVch|ryP MmfiV2FPT0WU
KU812 NIfqblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnflTWM2OD1zOT65OVc{KM7:TR?= NXfpfFZIW0GQR1XS
NCI-H441 NVr2fZFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPXNWhIUUN3ME2yNE4xODFizszN NUfNO4hCW0GQR1XS
Mewo Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXsU3hGUUN3ME2yNE4yOjh6IN88US=> M1;hW3NCVkeHUh?=
SK-MEL-24 NE\OPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD1VHk3UUN3ME2yNE4yPDd5IN88US=> M1nMU3NCVkeHUh?=
NCI-H727 NUK2Ro1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC3[ZFKSzVyPUKwMlI4ODRizszN MkHvV2FPT0WU
EKVX NIDldYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJyLk[wOkDPxE1? MoHlV2FPT0WU
RT-112 NFe4cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJyLk[xNlIh|ryP M3OzNXNCVkeHUh?=
CAMA-1 NXfBTWV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjoTWM2OD1{MD65PFA{KM7:TR?= MWrTRW5ITVJ?
SW900 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr3cotKSzVyPUKxMlAyPDlizszN M4T6THNCVkeHUh?=
NCI-H23 NYPp[ZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe3NVRCUUN3ME2yNU4yOjd5IN88US=> NWHMdHoxW0GQR1XS
SK-PN-DW MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrGd49KSzVyPUKxMlE3PDlizszN M{TG[XNCVkeHUh?=
BB30-HNC NI\h[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\hW4JKSzVyPUKxMlI4PDVizszN NWixb3NOW0GQR1XS
VM-CUB-1 NFLGdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD1{MT6zOVM3KM7:TR?= M{f1dnNCVkeHUh?=
IST-MEL1 NEHmUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj4fINKSzVyPUKxMlM3QTJizszN M1nQbXNCVkeHUh?=
CTB-1 M2PBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHezUWZKSzVyPUKxMlQ4PTVizszN NVrvbGdxW0GQR1XS
LCLC-103H Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ{LkG1PFIh|ryP Ml;QV2FPT0WU
PANC-03-27 M2\SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jOUWlEPTB;MkKuOVE3QSEQvF2= MknxV2FPT0WU
HTC-C3 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXwWZRKSzVyPUKyMlU2PTVizszN MU\TRW5ITVJ?
TE-8 M1W5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ|LkK1OlUh|ryP MY\TRW5ITVJ?
NCI-H292 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnWfGFKSzVyPUK1MlM2OzZizszN NEjMWXdUSU6JRWK=
COLO-680N MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnqTWM2OD1{NT62N|I6KM7:TR?= Mn;mV2FPT0WU
KYSE-520 NH;iXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zwN2lEPTB;MkWuOlQ1KM7:TR?= MnfBV2FPT0WU
NB10 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ4LkOxNVch|ryP MYTTRW5ITVJ?
NCI-H661 NUXYfVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ4LkS3NVMh|ryP MYHTRW5ITVJ?
GMS-10 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnpcplXUUN3ME2yOk45PjN6IN88US=> NHHQcIxUSU6JRWK=
NCI-H2122 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPfZJ5UUN3ME2yOk46QTl6IN88US=> NHP0c5dUSU6JRWK=
OVCAR-8 M{jRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ZTWM2OD1{Nz6wOlM5KM7:TR?= MVrTRW5ITVJ?
DJM-1 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LX[GlEPTB;MkeuNVQ2PCEQvF2= M{T5dXNCVkeHUh?=
UACC-893 M3jRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ5Lkm4O|gh|ryP MWfTRW5ITVJ?
C8166 NWG2WGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH30eIJKSzVyPUK4MlY6OzhizszN NYG1OXpHW0GQR1XS
NCI-H1693 M{OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPiTWM2OD1{OD62PVc2KM7:TR?= MWPTRW5ITVJ?
TYK-nu NHPpXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNyLkCzOFUh|ryP NXfUWXRIW0GQR1XS
SW1710 NGr3N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNyLkGyOkDPxE1? NE\adGxUSU6JRWK=
A375 M2P0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHTU4ZKSzVyPUOwMlMzPDNizszN MmLPV2FPT0WU
HMV-II NYTHZ|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\TRo1KSzVyPUOxMlM2QTJizszN NHOxTHdUSU6JRWK=
NCI-H2087 M4TkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LkXGlEPTB;M{GuOlM2OiEQvF2= MYTTRW5ITVJ?
CAL-54 NW[wd2lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNzLkeyOFEh|ryP MYPTRW5ITVJ?
HCC70 NYTkRY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i1NGlEPTB;M{KuNVM5PyEQvF2= MmfDV2FPT0WU
ES1 NFzBb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjudI1KSzVyPUOyMlMxPjJizszN NUfER3F[W0GQR1XS
NCI-H1355 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PreWlEPTB;M{OuNlA1KM7:TR?= NUDadlJsW0GQR1XS
CFPAC-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPiTWM2OD1|Mz6yN|MzKM7:TR?= NEjiSWJUSU6JRWK=
MKN28 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPKTWM2OD1|Mz6zPFA6KM7:TR?= M1vNWXNCVkeHUh?=
HDLM-2 M3faemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rnNWlEPTB;M{OuOlk{OSEQvF2= MnHIV2FPT0WU
PANC-10-05 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSyTWM2OD1|ND6xNFE1KM7:TR?= NEjWb5pUSU6JRWK=
SAS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXPTJEyUUN3ME2zOE41PTZ3IN88US=> M1SyR3NCVkeHUh?=
HCC1395 M13uTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN2LkexPFYh|ryP NIDmNXpUSU6JRWK=
8305C NILMT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\LVWhKSzVyPUO1Mlg1OTVizszN M2r2TXNCVkeHUh?=
KM12 NIDKPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITD[25KSzVyPUO2Mlc2PDdizszN M4PIVXNCVkeHUh?=
SW1116 M4ezUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN5LkW5PVIh|ryP M{\tOXNCVkeHUh?=
SK-MEL-1 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnKO2dvUUN3ME2zPE4{Ozh7IN88US=> NW\IRlhYW0GQR1XS
HCC2218 NXPVOXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3hOFlKSzVyPUO4MlY2OTlizszN M1;XUHNCVkeHUh?=
T84 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXsTWM2OD1|OD63OFA6KM7:TR?= MYnTRW5ITVJ?
ETK-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H3VmlEPTB;M{muNFIzKM7:TR?= NXzxb|V{W0GQR1XS
COLO-800 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnyZ3lbUUN3ME2zPU4{QDZ6IN88US=> NYLkd|g5W0GQR1XS
CAL-12T M4DCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;HTWM2OD1|OT61NlgyKM7:TR?= M3niZ3NCVkeHUh?=
ACN NEHUPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XLOWlEPTB;NECuOFkyOSEQvF2= M1fpOnNCVkeHUh?=
SJSA-1 NFzPOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRzLkG1PVYh|ryP NVPtSnpDW0GQR1XS
PSN1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPHZ2pKSzVyPUSxMlE4PDlizszN MYfTRW5ITVJ?
D-566MG MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRzLkKwPFYh|ryP M4DiNnNCVkeHUh?=
EGI-1 NF\wfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i1bWlEPTB;NEKuOFI5KM7:TR?= NX76VHhJW0GQR1XS
A204 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyzRoFCUUN3ME20Nk43Ozh6IN88US=> NYjGc2ZkW0GQR1XS
Saos-2 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTNTWM2OD12Mj64N|Y6KM7:TR?= M{PtenNCVkeHUh?=
SNU-C2B M2DGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR|Lk[4O|gh|ryP NHqz[lBUSU6JRWK=
HLE NUjifWtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTYfpUyUUN3ME20OE4xQDV4IN88US=> M{LndnNCVkeHUh?=
SW1463 NWjFZYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\STWM2OD12ND65PVcyKM7:TR?= M13GPHNCVkeHUh?=
DSH1 NEPiZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHrNW12UUN3ME20OU4xODN|IN88US=> Mn\EV2FPT0WU
MCF7 NVXIbXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLz[|dmUUN3ME20OU42ODVzIN88US=> MlrXV2FPT0WU
K5 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXQcGR{UUN3ME20OU46PDB3IN88US=> NF\6clJUSU6JRWK=
NCI-H358 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\uWWM4UUN3ME20O{4zOTVizszN M2DMcHNCVkeHUh?=
NCI-H2030 M3HtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTR5LkKzO|Qh|ryP NIjse5ZUSU6JRWK=
SW948 NVPzS49bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\zTWM2OD12Nz60OlQh|ryP MXzTRW5ITVJ?
BALL-1 NFvLXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTR5Lk[xOlgh|ryP Mof6V2FPT0WU
TE-9 M1nnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7rc|FxUUN3ME20O{46PThzIN88US=> NFvoOHlUSU6JRWK=
SK-N-FI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLvT2ZqUUN3ME20PE4xOzV6IN88US=> M{P1e3NCVkeHUh?=
KALS-1 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LIdWlEPTB;NEiuNVI5QSEQvF2= MVPTRW5ITVJ?
HO-1-N-1 NFPFN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofUTWM2OD12OD63OFQ2KM7:TR?= M{LpfnNCVkeHUh?=
NCI-H2452 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTR7LkGxOVIh|ryP MlnsV2FPT0WU
OC-314 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR7Lk[4N|Qh|ryP MoX1V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03181126 Recruiting Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT02520778 Recruiting Drug: Navitoclax|Drug: Osimertinib Advanced Lung Non-Squamous Non-Small Cell Carcinoma|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.T790M|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Completed Drug: ABT-263 Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02079740 Recruiting Biological: Navitoclax|Drug: Trametinib Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic Malignant Solid Neoplasm|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT00887757 Completed Drug: ABT-263|Drug: gemcitabine Solid Tumors AbbVie|Genentech Inc. September 2009 Phase 1
NCT00888108 Completed Drug: ABT-263|Drug: Docetaxel Solid Tumor Abbott|Genentech Inc. July 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID